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Disease burdenThe drivers of vaccine development are many and varied. They include, for example, recognition of the
burden of a vaccine-targeted disease, prioritisation of the multiple problems associated with a disease,
consideration of the differing socio-economic situations under which vaccines are used, the influence
of advocacy groups, and assessment of the feasibility of large-scale vaccine manufacture and distribution.
In the field of human health, data-driven development of vaccines is becoming increasingly common
through the availability of reliable information on the Global Burden of Disease (GBD) and stringent eval-
uations of vaccination programmes utilising empirical data on costing and effectiveness, and standard-
ised cost-effectiveness thresholds. The data generated from such analyses allow policymakers,
implementing partners, industries and researchers to make decisions based on the best, and most contex-
tually relevant, available evidence. In this paper, we wish to explore the current use of economic and
social data for the development of veterinary vaccines. Through comparison with the development of
human vaccines, we will look for opportunities in animal health sciences to better integrate socio-
economic data and analyses into the process of veterinary vaccine selection, development, and field
implementation. We believe that more robust animal health impact assessments could add value to vet-
erinary vaccine development by improving resource allocation and animal disease management.
 2018 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Investment in health interventions – be that in humans or in
non-human animals, at the individual or group-level (e.g. farm,
region, and nation) – requires decisions to be made on resource
allocation within a finite budget. Making these health decisions
evidence-based requires on the one hand, data on the burden of
diseases and on the other, data on the cost and acceptability of
the interventions used to combat these diseases within particular
contexts. With such data, the optimal combination of interventions
can be developed and implemented. In addition, disease controlprogrammes require data on the safety and effectiveness1 of vacci-
nes, the quality of which depends on the robustness of pharmacovig-
ilance systems and the monitoring of adverse events in vaccinated
populations [1].
In the field of human health, there has been vast progress made
on understanding and quantifying the global burden of diseases
across populations, time and space [2]. There are guidelines to help
countries making decisions about vaccination [3], as well as speci-
fic guidance on the socio-economic evaluation of vaccine and vac-
cination strategies [4]. In this regard, cost-effectiveness analyses
are the most commonly used economic tool in human health care
settings. This approach uses proxy outcomes, such as $ per disabil-
ity adjusted life years (DALYs) saved or quality adjusted life years
(QALYs) averted, to judge the cost-effectiveness of vaccination pro-
grammes in human populations. For the adoption of monovalent
rotavirus vaccine alone, sixty cost-effectiveness analyses were to
date performed [5], demonstrating the high degree to which this‘vaccine
vaccina-
s from
2 L.F. Thomas et al. / Vaccine xxx (2018) xxx–xxxtype of analysis is integrated into human vaccinology. Yet, the
same cannot be said for veterinary vaccinology. A search in Web
of Science [6] on the 19th July 2018 showed, for instance, that by
using the string search (‘human vaccin*’ AND (cost-effectiveness
OR profitability OR cost-benefit)) 1104 results were obtained,
while (‘animal vaccin*’ AND (cost-effectiveness OR profitability
OR cost-benefit)) only provided 160 results. This observation
underlines the paucity of socio-economic analyses in veterinary
vaccinology. Similarly, the data available from pharmacovigilance
systems to explore the safety and effectiveness of veterinary vacci-
nes in the field are, for the most part, of poor quality. In fact, the
data on adverse effects and vaccine effectiveness are generally
absent due to high under-reporting [7]. So, why are the approaches
to the development of veterinary and human vaccines so different?2. What are the main differences between human and
veterinary vaccine development?
The path from the identification of an immune stimulating
agent to a marketable vaccine requires significant investment of
finance and time, whether the vaccine is intended for human or
non-human animals [8,9]. We highlight here however, two specific
areas where development of veterinary vaccines lag behind. These
being the ability to prioritise potential vaccine targets based upon
the quantified burden of diseases and the use of extensive observa-
tional field studies in the post-licensure phase to evaluate vaccine
safety, effectiveness, and cost-effectiveness under field conditions
[10–12].2.1. Defining priorities for veterinary vaccine development
The context in which human and non-human animal vaccines
are developed differs and relates to the diverse value propositions
attached to vaccine recipients (i.e. humans and non-human ani-
mals). The value of non-human animals has always been dictated
by human society and its culture [13] and have varied across time
and space, in relation to different roles attributed to non-human
animals in society (e.g. food production, leisure, labour and com-
pany) [11]. In fact, the willingness to invest in non-human animal
health interventions (e.g. in research, development, and health
programme implementation) often reflects the different values
(e.g. sentimental, and financial) attached to non-human animal
species and possible fears related to their diseases (e.g. health).
Today, pets have become important companions in life for humans
– hence the term ‘companion animals’ – and their integration into
human society has increased, especially in modern Western soci-
eties. The market of companion animal vaccines has grown fastest,
reflecting an increase in Western investments and concerns in pet
wellbeing and healthy practices, as well as in the number of pet
owners worldwide. By contrast, the market growth of farmed ani-
mal (i.e. livestock and fish) vaccines has mostly been driven by
zoonotic diseases (i.e. diseases transmissible to humans) and dis-
eases with significant effects on international trade (i.e. diseases
affecting the market share of dominant powers) [14,15]. Including,
for instance, highly pathogenic avian influenza (HPAI), foot and
mouth disease (FMD), and porcine reproductive and respiratory
syndrome (PRRS). In other words, farmed animals have been some-
what marginalised from the debates on veterinary vaccine devel-
opment and their vaccines promoted purely as objects of human
safety and the global economy [16,17]. The individual value of
farmed animals as living beings, as well as their contextual value
to specific human populations has therefore been neglected.
Although largely absent from discussions of veterinary vaccines,
many subtle and chronic diseases that are restricted to farmed ani-
mals (i.e. enzootic diseases) have, however, a significant impact onPlease cite this article in press as: Thomas LF et al. Using economic and socia
human vaccinology. Vaccine (2018), https://doi.org/10.1016/j.vaccine.2018.10.farmed animal health and welfare and represent a significant bur-
den for multiple societies, especially in the poorest and most vul-
nerable countries [17].
Initiated in 1991, the Global Burden of Disease, Risk Factors &
Injuries (GBD) study has provided decision makers with ‘timely,
local, and valid estimates’ of the burden of many human diseases,
injuries and sequelae of diseases [2]. From this work, priorities can
now be set according to the context and the quantified burden of a
disease upon a human population in terms of DALYs [18]. Follow-
ing the same approach, some work has been conducted to quantify
a global burden of animal diseases. This initiative has so far been
limited to zoonotic diseases with the creation of a Zoonotic Disabil-
ity Adjusted Life Years (zDALYs) metric [19,20]. Therefore, we are
still lacking of a standardised process to quantify the global burden
of animal diseases as a whole [21,22]. This paucity of data results,
in turn, in an inability to accurately prioritise animal diseases or
establish a baseline for the cost-effectiveness assessment of animal
disease interventions, such as vaccination, thereby giving space to
dominant and powerful voices in the allocation of resources for the
control of animal diseases, such as FMD and HPAI [15].
Similarly, although commonly used as a tool for the post-
licensure evaluation of human vaccine effectiveness, large-scale
post-introduction observation studies are rarely conducted for vet-
erinary vaccines due to a lack of resources and poor demonstration
of return on investment [11,23]. In addition, when they exist, as for
FMD vaccines in Turkey [24], they are rarely coordinated as part of
a national policy, making their implementation more difficult.
2.2. Evaluating safety, effectiveness, and cost-effectiveness of
veterinary vaccines under field conditions
With a handful of notable exceptions, socio-economic analyses
of veterinary vaccines have mostly relied on ex-ante modelling
studies [25], including models demonstrating the economic benefit
of vaccination programmes against Rift Valley Fever in Kenya [26],
rabies in Tanzania [27], brucellosis in Mongolia [28], FMD in Den-
mark [29], UK [30] and the USA [31,32], as well as a variety of anal-
yses for HPAI vaccination campaigns [33–37]. To maximise their
utility, there is, however, a need for further validation of these
models with empirical data collected in the field during the roll-
out of vaccination campaigns; something that remains relatively
rarely applied in the veterinary sciences.
Although several studies exist which analyse the social and/or
economic impact of veterinary vaccines, it is very difficult, if not
impossible, to compare them due to the variety of methods used
and inconsistency in the outcomes measured. This includes, for
instance, outcomes such as the determination and comparisons
of the total costs of various national vaccination strategies against
HPAI [38–42], the savings made on alternative mitigation strate-
gies after the adoption of a vaccine [43], or the increase in house-
hold expenditure attributable to a vaccine adoption [44]. Despite
the inherent importance of these analyses on an individual basis,
the lack of: (1) a standardised metric for quantifying the global
burden of animal diseases; (2) standardised methods for determin-
ing the cost-effectiveness of veterinary vaccines; and (3) standard-
ised cost-effectiveness thresholds within the veterinary sciences,
prevents the comparison and prioritisation of vaccine interven-
tions across animal species, pathogens and geographical localities.
After the thalidomide disaster of the 1960s, pharmacovigilance
came to the fore in human health placing heavy responsibility on
vaccine manufacturers, public health officials, vaccine programme
managers and front line staff to monitor, report and act on human
vaccine adverse events [45,46]. By contrast, although recognised
and supported by different legislations around the world, veteri-
nary pharmacovigilance schemes in Europe, USA, Canada, Australia
and South Africa (e.g. European directive 2004/28/EC and regula-l data to improve veterinary vaccine development: Learning lessons from
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reporting of suspected adverse events [47]. In this context, the
UK is seen as the exemplary scheme within the EU, with the Veteri-
nary Medicines Directorate (VMD) regularly publishing reported
events in the Veterinary Record [7]. Interestingly, the majority of
adverse events reported in the UK and France are in companion
animals and the majority of reports are from veterinarians with
similar patterns observed elsewhere, indicating a lack of engage-
ment from various stakeholders outside the veterinary practise of
companion animals [47,48]. Moreover, studies in Europe have
demonstrated a large degree of under-reporting by veterinarians,
undermining the strength of the current systems [7,48]. As a result,
the success of veterinary pharmacovigilance remains today ques-
tionable, especially given past crises related to the introduction
of new veterinary vaccines in the field. A particularly striking
example, highlighting the need for both larger scale post-
introduction studies and stringent pharmacovigilance in animal
health, was the increased incidence in Bovine Neonatal Pancytope-
nia (BNP) in calves born to dams previously vaccinated with Preg-
Sure Bovine Viral Diarrheal Vaccine (Pfizer animal health) after its
introduction in several European countries and New Zealand [49–
53]. This severe haemorrhagic disease of calves was characterised
by massive thrombocytopenia and some degree of leukopenia,
resulting in external and internal haemorrhage around 10 days of
age. The cause was elucidated to be vaccine-induced maternal
alloantibodies, with an incidence of between 6 and 200 per
100,000 vaccinated dams [52]. Importantly, there was an approxi-
mately 3-year delay between the launch of the PregSure vaccine
and the increased incidence of BNP, and the incidence of disease
has differed enormously between and within countries due to dif-
ferences in genetics and/or vaccine protocols [52,53]. Factors such
as these indicate why safety decisions based on the results of clin-
ical trials on small numbers of homogenous animals – as are often
performed in veterinary vaccine development [11] – are not suffi-
cient for the detection of potential adverse events at a population
level. In addition, although current legislation obliges pharmaceu-
tical producers and end-users to report adverse effects, including
lack of vaccine effectiveness, frequent non-reporting of adverse
events makes such a system particularly weak in monitoring the
lack of expected vaccine effectiveness [7,23].
Having examined some of the main differences between human
and non-human animal vaccine development, we now present an
example of impact assessment conducted in human vaccinology
and discuss its implications for the future of veterinary vaccine
research and animal health policy. In doing so, we wish to chal-
lenge the current processes of socio-economic data collection and
analysis in veterinary sciences for the development and implemen-
tation of new vaccine policies.3. Learning lessons from human vaccine development: The
socio-economic analysis of rotavirus vaccination in Malawi
Diarrheal disease is one of the leading causes of death in chil-
dren under 5 worldwide, with rotavirus as the number one causa-
tive agent [54]. Rotaviral enteritis was estimated to be responsible
for 1,865,000 (95% Uncertainty Interval [U.I.]: 14,43100–22,74600)
DALYs lost globally in 2010 [10]. In the sole region of Africa, rota-
virus has been estimated to cause around 2,557,000 (95% U.I.:
1,901,000–3,026,000) episodes of severe diarrhoea and 95,000
(95% U.I.: 52,500–151,300) deaths every year [55]. The global alli-
ance for vaccines and immunisation (GAVI) provides support for
vaccination programmes in eligible countries, based upon their
gross national income [56]. Prior to the introduction of rotavirus
vaccination in GAVI-eligible countries, the programme was the
subject of an ex-ante modelling study. This study suggested that,Please cite this article in press as: Thomas LF et al. Using economic and socia
human vaccinology. Vaccine (2018), https://doi.org/10.1016/j.vaccine.2018.10.across eligible countries, the vaccine would be very cost-effective
($43/DALY averted) [57]. Malawi was one of the first African coun-
tries to introduce monovalent rotavirus vaccine within their
national childhood vaccination programme with the support of
GAVI. In collaboration with the Malawi National Immunisation
Technical Advisory Group (NITAG), a national vaccine evaluation
programme was established, comprising of several interlinking
studies. These included sentinel surveillance to investigate chang-
ing disease incidence and distribution of rotavirus genotypes,
matched and unmatched case-control studies and a large prospec-
tive population based cohort study investigating vaccine effective-
ness and cost-effectiveness [58]. These studies provided country-
specific empirical data on vaccine effectiveness (VE), including
within sub-populations, such as those with co-morbidities (e.g.
HIV and stunting), and the cost-effectiveness of the vaccination
campaign. Cost-data were captured at the level of the patient,
household, healthcare provider and national vaccination campaign,
and using the TRIVAC 2.0 model projected the incremental cost-
effectiveness ratio (ICER) over a 20-year period (2014–2033). Over-
all, the Malawi’s monovalent rotavirus vaccine demonstrated 63%
VE, with no significant reduction in VE in HIV-infected or stunted
children. This resulted in a 43% reduction in the burden of rotavirus
in hospitals. To date, no specific genotype has emerged to suggest
vaccine escape and the incremental cost-effectiveness ratio of
introducing the vaccine was determined to be $10/DALY averted
[59,60]. Given Malawi’s 2016 GDP per capita of approximately
$300, this vaccine appears, therefore, to be highly cost-effective
according to the WHO threshold [61].
Overall, these data have provided a strong evidence-base for
continued support of the vaccination campaign, especially as
Malawi will be required to increase the proportion of their co-
payment for the vaccine over time (the GAVI-alliance currently
subsidises much of the vaccine cost). Moreover, the TRIVAC model
developed with the support of the Pan-American Health Organiza-
tion (PAHO) has also been made available to the majority of low
and middle-income countries. It is used by national teams to eval-
uate the impact of new childhood vaccinations, and specifies
parameters to calculate costs of vaccination, prevented health-
care costs, number of cases averted and the incremental cost-
effectiveness ratio in terms of $/DALY averted [62]. Fig. 1 demon-
strates the breath of data collected in post-introduction studies
and incorporated into the TRIVAC model, which influence the
context-specific incremental cost-effectiveness ratio. Parallel to
these specific models and systems of impact assessment, a project
led by theWorld Health Organization, assisting members to choose
health interventions that are cost-effective (WHO-CHOICE project),
has developed threshold guidelines. These latter suggest that an
intervention costing less than 3 times the per Capita GDP per DALY
averted is cost-effective, while interventions costing less than 1
should be considered highly cost-effective [61]. There is debate,
however, around the validity of these thresholds recommended
by WHO-CHOICE, with some suggesting that, as an independent
metric, it hardly considers what a country can actually afford or
is willing to pay for an intervention. Other ways of determining
the cost-effectiveness of interventions have therefore been sug-
gested [63]. Yet, the underlying requirement still remains a need
for robust and empirical data on both the global burden of disease
and the cost-effectiveness of interventions.
By using this example, we illustrate how post-marketing obser-
vational field evaluations provide an ideal opportunity to collect
empirical data allowing the determination of vaccine safety, effec-
tiveness, and cost-effectiveness. We selected an example from the
sciences of human vaccinology as, to our knowledge, there is no
equivalent study that would demonstrate an economic analysis
being embedded into a veterinary vaccination campaign. Building
on this, we wish to highlight the current data needs for animall data to improve veterinary vaccine development: Learning lessons from
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Fig. 1. Data influencing the national level incremental cost-effectiveness of a vaccination programme. (Adapted from the TRIVAC 2.0 model as presented in Bar-Zeev et al.
[59,60]).
4 L.F. Thomas et al. / Vaccine xxx (2018) xxx–xxxhealth, and, more specifically, vaccination decisions, and propose
recommendations for moving forward and improving the develop-
ment of veterinary vaccines.4. What are the opportunities for improving the use of
economic and social data in veterinary vaccinology?
A better understanding of the socio-economic benefits of ani-
mal health interventions, starts from an understanding of the bur-
den of animal diseases in specific contexts of animal use and value
attribution, along with the demand for and acceptability of differ-
ent intervention options. In the particular context of vaccine, it is
subsequently important to evaluate their safety, effectiveness
and cost-effectiveness, since each of these aspects influence the
acceptability of the end-user vaccination.
Following the precedent set by the human GBD project, the first
planning workshop of the Global Burden of Animal Diseases
(GBADs) programme was held this year at the World Organisation
for Animal Health (OIE), in Paris [64]. This initiative aims to
develop a system that regularly collects, validates, analyses and
disseminates information on the socio-economic impacts of animal
diseases and disease interventions at global, national and sector
levels. GBADs will draw on the core principles of the GBD pro-
gramme to assess animal disease losses and will incorporate prin-
ciples of economics and other social sciences to look at net losses
and explore current levels of expenditure. In addition, GBADs will
support a process of impact differentiation between species and
production systems at a national, regional and global level in order
to identify points of weak resource allocation between diseases
and within specific disease programmes. In quantifying the global
and relative burden of different animal diseases, this project will
present a strong social and economic case for animal health invest-
ments and sustainable vaccine interventions.
Currently, post-introduction studies are rare in veterinary vac-
cinology because of their high cost and resource requirements
and are not perceived as being a good value for money investment.Please cite this article in press as: Thomas LF et al. Using economic and socia
human vaccinology. Vaccine (2018), https://doi.org/10.1016/j.vaccine.2018.10.This type of work, however, represents one of the best ways in
which data can be collected to better understand the safety, effec-
tiveness, acceptability and cost-effectiveness of vaccines under
field conditions. Learning from the useful information generated
in human vaccinology, animal health would benefit from vaccina-
tion campaigns being designed with integrated post-introduction
observational studies. This includes conducting long-term, field-
based, prospective cohort studies that capture the full costs of
intervention at different levels (e.g. individual, local, regional,
national, or international) and assess the occurrence of possible
adverse outcomes and externalities, such as those observed during
the FMD crisis in the United Kingdom [25]. These studies also pro-
vide an opportunity to understand the dynamics, the logistics and
the distribution chains of vaccine interventions and the possible
challenges of their implementation, especially in terms of societal
acceptability. By engaging with various stakeholders, faced with
the potential impacts of new vaccine interventions and policies,
these studies would also increase the representation of these
actors in the design of new vaccine policy and strengthen their par-
ticipation in the reporting of adverse effects [23]. When public
funds are being utilised in vaccination programmes, these analy-
ses, and the engagement with stakeholders, are essential for ensur-
ing value-for-money to society, and this societal value should be
considered from the very decision whether to develop a candidate
vaccine through to delivery. This way, the re-parameterising of ex-
ante models with empirical data can improve the quality of our
predictive modelling work, the vaccine interventions we design,
as well as the decisions we make (Fig. 2). Dialogue with stakehold-
ers and an understanding of willingness-to-pay (from the private
and the public sectors) may also foster the development of cost-
effectiveness guidelines such as those available from WHO-
CHOICE, against which interventions can be measured.
Implementing our recommendations, both in terms of data col-
lection and the establishment of large post-introduction studies for
vaccine interventions may be difficult. Resources will be needed
for the development of baselines on which to prioritise diseases
and, once decided and selected, for the standardisation of thel data to improve veterinary vaccine development: Learning lessons from
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Fig. 2. Data driven veterinary vaccine development.
L.F. Thomas et al. / Vaccine xxx (2018) xxx–xxx 5vaccine protocols and surveillance systems on which the vaccina-
tion programme evaluation will be based. These will require the
interpretation and use of different sets of data, which in itself
may pose challenges related to the requirement for transdisci-
plinary collaboration, including an understanding of the data, lan-
guage and expectations of different disciplines and institutions
[65]. In addition, ascertainment of animal vaccination status can
be a major challenge [58], with valid individual data often lacking,
especially in the global South where individual animal electronic
records are not available [11]. Robust data, however, are available
for larger farms and those involved in rolling out vaccination pro-
grammes should be strongly encouraged to improve record keep-
ing for later analysis of vaccine coverage, efficacy and adverse
events. The determination of vaccine effect in a setting where mul-
tiple interventions may be implemented at once might also be dif-
ficult, as well as adjusting for confounding effects between
vaccinated and non-vaccinated individuals and assuring quality
and consistency of data collection at large scales [58]. Neverthe-
less, such an initiative will allow the prioritisation of animal dis-
eases and the evaluation of vaccination programmes based on
empirical evidence, leading to more effective results for the health
of animals and the moral development of societies. If the animal
health sciences are to take up the challenge presented here, we
believe that this will allow the evolution of thinking from advocacy
based on expert opinion to that of multi-source decision-making
based on data allowing optimisation and sustainability of interven-
tion programmes at all levels.5. Summary
The contexts of human and non-human animal vaccinology dif-
fer; yet, there is scope for the field of veterinary vaccinology to bet-
ter utilise socio-economic approaches to demonstrate the value of
population-based vaccination campaigns. Enhanced appreciation
of the economic and social benefits of veterinary vaccination will
assist their uptake by individual animal owners or national govern-
ments and, in turn, assist the attainment of the sustainable devel-
opment goals. As a community, we have built strong predictive
models, but these now need to be reviewed and validated with
empirical data, preferably collected during large post-
introduction studies. The type of work we suggest comes at a cost
and requires vision and leadership from public bodies, industries
and scientists. The benefits are, however, immense and willPlease cite this article in press as: Thomas LF et al. Using economic and socia
human vaccinology. Vaccine (2018), https://doi.org/10.1016/j.vaccine.2018.10.improve science, budget allocation and pharmacovigilance of vet-
erinary vaccines.
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